Thomas E Garrison Net Worth

The estimated Net Worth of Thomas E Garrison is at least $2.44 Million dollars as of 2 December 2009. Thomas Garrison owns over 350,000 units of Bio-Path Inc stock worth over $2,435,984 and over the last 15 years Thomas sold BPTH stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Thomas Garrison BPTH stock SEC Form 4 insiders trading

Thomas has made over 2 trades of the Bio-Path Inc stock since 2009, according to the Form 4 filled with the SEC. Most recently Thomas bought 350,000 units of BPTH stock worth $87,500 on 2 December 2009.

The largest trade Thomas's ever made was buying 400,000 units of Bio-Path Inc stock on 13 October 2009 worth over $100,000. On average, Thomas trades about 375,000 units every 25 days since 2009. As of 2 December 2009 Thomas still owns at least 2,511,324 units of Bio-Path Inc stock.

You can see the complete history of Thomas Garrison stock trades at the bottom of the page.

What's Thomas Garrison's mailing address?

Thomas's mailing address filed with the SEC is 3293 HARRISON BLVD STE 230, , OGDEN, UT, 84403.

Insiders trading at Bio-Path Inc

Over the last 16 years, insiders at Bio-Path Inc have traded over $171,456 worth of Bio-Path Inc stock and bought 1,226,067 units worth $451,466 . The most active insiders traders include Capital, Llc Armistice Capi..., Thomas E Garrison, and Michael J. Garrison. On average, Bio-Path Inc executives and independent directors trade stock every 423 days with the average trade being worth of $156,477. The most recent stock trade was executed by Capital, Llc Armistice Capi... on 18 January 2019, trading 64,457 units of BPTH stock currently worth $171,456.

What does Bio-Path Inc do?

bio-path is a publicly traded biotechnology company focused on developing therapeutic products utilizing its proprietary dnabilize™ technology designed to distribute nucleic acid drugs throughout the human body with a simple intravenous infusion. the company’s initial focus is in oncology. bio-path’s lead product candidate, prexigebersen, (bp1001), is in phase ii clinical trials for aml in combination with ldac in elderly de novo patients. the safety segment of the phase ii trial for prexigebersen + dasatinib in blast-phase and accelerated phase cml patients is expected to begin in 2017. bio-path’s second drug candidate, bp1002, is ready for the clinic where it will be evaluated in lymphoma and solid tumors. the technology behind prexigebersen is called dnabilize™ technology. dnabilize is a liposomal antisense dna platform with two critical improvements in oligonucleotide therapeutics. the main benefits to the patient are, 1: we have never had a single patient experience thrombocytopen

Complete history of Thomas Garrison stock trades at Bio-Path Inc

Bio-Path Inc executives and stock owners

Bio-Path Inc executives and other stock owners filed with the SEC include:

• Peter Nielsen,
  Chairman of the Board, President, Chief Executive Officer, Co-Founder, Chief Financial Officer, Treasurer
• Peter H. Nielsen MBA,
  Co-Founder, Chairman, CEO, Pres, CFO & Treasurer
• Douglas Morris,
  Director, Secretary, Director of Investor Relations
• Douglas P. Morris,
  Co-Founder, Director of Investor Relations, Sec. & Director
• Martina Molsbergen,
  Independent Director
• Heath Cleaver,
  Independent Director
• Paul Aubert,
  Independent Director
• Victoria Lake Rac,
  Regulatory Consultant
• Dr. Jeffery Lancet M.D.,
  Consultant
• Dr. Thomas A. Walker Ph.D.,
  Consultant
• Dr. Alan MacKenzie Ph.D.,
  Consultant
• Dr. Ana Tari Ashizawa Ph.D., MBA,
  Sr. VP of Research, Devel. & Clinical Design
• Anthony Price,
  Sr. VP of Fin., Accounting & Admin.
• Amy Sing,
  Director
• Ulrich W. Mueller,
  Chief Operating Officer
• Michael J. Garrison,
  Director
• Mark P Colonnese,
  Director
• Capital, Llc Armistice Capi...,
  
• Gillian C Ivers Read,
  Director
• Thomas E Garrison,
  Director
• Aline Sherwood,
  Director